Product hub: A reproducible and scalable Huntington’s disease human cell model
Posted: 22 June 2022 | bit.bio | No comments yet
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
What challenge is the industry facing with cell models, in your opinion?
During my scientific career, I have extensively studied how signalling molecules and transcription factors impose an identity on neurons during development of the central nervous system and applied this knowledge to generate different subtypes of dopaminergic neurons from induced pluripotent stem cells (iPSCs). As a senior scientist at bit.bio, I am now using this expertise to develop scalable and defined human neuronal cell models for drug discovery as well as to address fundamental questions in neuroscience.
Related content from this organisation
- Product hub: A reproducible and scalable Huntington’s disease human cell model
- Improving Huntington’s disease drug discovery with new reproducible disease models
- bit.bio raises $103 million in first close of Series B financing
- Transcriptional reprogramming rescues vascular fate of misidentified pluripotent cell‑derived epithelial cells
- Drug development in stem cell-derived liver organoid models
Related topics
Biopharmaceuticals, CNS, Drug Discovery, In Vitro, Neurosciences, Stem Cells
Related conditions
Huntington's disease
Related organisations
Bit Bio
